Monopar Therapeutics Inc. Gains 64.58%
Monopar Therapeutics Inc. (MNPR:NASDAQ) shot up at $3.95, a gain of 64.6%. On Wed, Sep 11, 2024, MNPR:NASDAQ hit a New 2-Week Intraday High of $2.47. The stock got featured on our News Catalysts scanner on Thu, Sep 12, 2024 at 10:32 AM in the 'BIOTECH' category. From Wed, Aug 28, 2024, the stock recorded 55.56% Up Days and 30.00% Green Days
The share price of the company has been moving sideways in recent weeks.
About Monopar Therapeutics Inc. (MNPR:NASDAQ)
Monopar Therapeutics Inc is the United States-based clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. Its pipeline products comprise of Validive, Camsirubicin, and MNPR-101.
Top 10 Gainers:
- Calithera Biosciences, Inc. (CALA:NASDAQ), 300%
- Edgio Inc Com (EGIO:NASDAQ), 118.7%
- Visionary Education Technology Holdings Group Inc. (GV:NASDAQ), 117.73%
- Oblong Inc. (OBLG:NASDAQ), 92.92%
- SRAX, Inc. (SRAX:NASDAQ), 66.67%
- Monopar Therapeutics Inc. (MNPR:NASDAQ), 64.58%
- Till Capital Ltd. (TIL:NASDAQ), 56.69%
- Manitex International, Inc. (MNTX:NASDAQ), 47.77%
- Tenon Medical Inc. (TNON:NASDAQ), 45.21%
- Smart for Life Inc. (SMFL:NASDAQ), 42.35%